menu
    • menu
    [{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Senza5 CART5","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ University of Pennsylvania"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vittoria Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vittoria Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ Vittoria Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Vittoria Biotherapeutics \/ Vittoria Biotherapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Vittoria Biotherapeutics

    Menu

    Vittoria Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIPER-101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Trial of VIPER-101

                            Details : VIPER-101 is a CD5 deleted CAR-T Cell and Gene therapy drug which is being developed as an investigational for the treatment of patients having T-cell Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 19, 2024

                            Lead Product(s) : VIPER-101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Valley Forge Investment Corporation

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Vittoria Biotherapeutics Raises $25M To Propel Groundbreaking Cell Therapies

                            Details : The proceeds will support the company’s Phase 1 trial of its lead oncology candidate, VIPER-101, an autologous, dual-population T cell therapy, as a potential treatment of T-cell Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            November 12, 2024

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Valley Forge Investment Corporation

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Senza5 CART5

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of Pennsylvania

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

                            Details : Senza5 CART5 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 17, 2024

                            Lead Product(s) : Senza5 CART5

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of Pennsylvania

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

                            Details : VIPER-101 is a CD5 deleted CAR-T Cell and Gene therapy drug which is being developed as an investigational for the treatment of patients having T-cell Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 07, 2023

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Valley Forge Investment Corporation

                            Deal Size : $15.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Nov...

                            Details : The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma, into the clinic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            November 14, 2023

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Valley Forge Investment Corporation

                            Deal Size : $15.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Vittoria Biotherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Thera...

                            Details : Vittoria will obtain rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform which will support its Senza5 technology to enhance efficacy of T-cell therapies including, Viper 101, a gene-edited, autologous, dual-population cell ther...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : VIPER-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth